Beyond the immediate cash infusion, the deal structure positions Aligos to collect up to $420 million in future clinical, regulatory, and sales milestones. The agreement also entitles the South San Francisco-based biopharmaceutical firm to tiered, high-single-digit royalties on net sales within Amoytop’s territory. While the stock closed the regular session up 4.7% at $5.85, the company remains down 37% year-to-date, making the partnership a critical pivot for investor sentiment.

Aligos maintains full control over development and commercialization of the treatment in all other major markets, including the U.S., Europe, and South Korea. Chief Executive Lawrence Blatt confirmed that Amoytop plans to initiate clinical testing of the antisense oligonucleotide in China during the third quarter, marking a rapid expansion of the drug's global footprint.